Truist Securities reiterated a Hold rating on agilon health Inc (NYSE: AGL) with a $112 price target, reflecting 17% upside from the stock’s last close of $95.92.
The rating follows a non-deal roadshow in New York City last week, during which agilon management outlined progress in clinical programs, payer contracting and operational execution. The company’s stock has surged 881% over the past six months, closing at $93.79 on August 21.
Analyst Jailendra Singh noted agilon’s improved data visibility and stronger foundation, with management shifting focus from stabilization to value creation. Core business optimization is expected to continue through 2027, followed by a planned disciplined return to market expansion in 2028.
Agilon reported second-quarter 2026 earnings per share of $1.04, exceeding the $0.08 forecast, and revenue of $1.49 billion, above the $1.44 billion estimate. The company subsequently raised its full-year outlook. InvestingPro’s fair value estimate for agilon stands at $136.88, implying additional upside beyond Truist’s target.
